|Bid||0.7200 x 0|
|Ask||0.7400 x 0|
|Day's Range||0.7200 - 0.7800|
|52 Week Range||0.7200 - 2.4900|
|Beta (5Y Monthly)||3.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 29, 2023 - Jun 04, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.78|
Aurora Cannabis (NASDAQ: ACB) has been struggling for years. The stock is trading down to well under $1 per share, and another reverse stock split is inevitable for the company. Aurora Cannabis' stock price fell 96% over the past three years.
Investors looking to add quality growth stocks to their equity portfolio can consider buying Well Health right now. The post 2 TSX Stocks to Buy This Month and 1 to Avoid appeared first on The Motley Fool Canada.
One was once a favorite among cannabis investors, but the other could become the top cannabis contender.
Cannabis stocks were up this week, as the market began to turn, but how long will it last, and is more growth coming? The post What’s Happening With Cannabis Stocks in May 2023? appeared first on The Motley Fool Canada.
Here's my take on whether Aurora Cannabis (TSX:ACB) is worth adding to a growth portfolio right now, given its growth prospects and fundamentals. The post Aurora Cannabis: Time to Light Up Your Portfolio? appeared first on The Motley Fool Canada.
It's been roughly five years since Canada legalized cannabis, and it's been an unpleasant ride for investors in Aurora Cannabis (NASDAQ: ACB), one of Canada's leading growers and operators. The company became a penny stock after surging to over $120 per share in 2018. While some may hope for a tremendous comeback story, sometimes a business model just isn't good.
Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, and a leading manufacturer and supplier of dried flower for medical patients worldwide, today announced the expansion of its portfolio in Germany with the launch of two new cannabis flower products for patients. Pedanios 27/1 FRG CA and Pedanios 29/1 SRD CA are dried cannabis flower with high tetrahydrocannabinol (THC) content. With these new therapeutic options now avai
Explore a promising marijuana stock that outshines Aurora Cannabis. Unveil the investment opportunity to boost your cannabis portfolio. The post 1 Marijuana Stock I’d Buy Over Aurora Cannabis appeared first on The Motley Fool Canada.
Marijuana stocks have fallen out of favor in the last two years. The Canadian producers Aurora Cannabis (NASDAQ: ACB) and Tilray Brands (NASDAQ: TLRY) are two of the most popular marijuana companies. Aurora Cannabis has been investors' favorite among pot stocks for a while.
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, today announced the launch of a new tracking program designed to support and empower cannabis patients on their wellness journey.
Today announced a fresh lineup of innovative products. Coming soon to patients at Aurora Medical and ...
Aurora Cannabis (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, today announced a fresh lineup of innovative products. Coming soon to patients at Aurora Medical and to consumers at retail stores across the country, the company's expanded portfolio includes newly developed cultivars, strain-specific gummies and aromatic vapes. Flower products include two original strains from Occo, Aurora's esteemed breeding program: Pink Diesel '71 and Moon Berry.
Aurora Cannabis Inc. ("Aurora" or the "Company") (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, today announced that it has repurchased an aggregate of approximately $22.3 million (US$16.6 million) principal amount of its convertible senior notes ("Notes") in multiple transactions since the start of April 2023 at a total cash cost, including accrued interest, of $16.7 million (US$12.4 million) and $5.3 million (US$4.0 million), including accrued interest, satisfied
April 20th has a special significance for the cannabis industry. Three of those companies have especially attracted investors' attention in recent years -- Aurora Cannabis (NASDAQ: ACB), Curaleaf Holdings (OTC: CURLF), and SNDL (NASDAQ: SNDL) (formerly known as Sundial Growers). Aurora Cannabis is the worst of the group, with its share price plunging more than 80%.
Despite losing most of their value, these former Wall Street darlings have been popular buys among billionaire money managers.
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, and MedReleaf Australia today announced the launch of IndiMed Tempo 26, a range of new higher THC dried cannabis products for qualified patients under the MedReleaf Concession Scheme (MCS). Tempo 26 will add to the portfolio of products available, giving doctors the ability to prescribe from a wider range of options for medical cannabis patients.
The Canadian government's decision to license over 1,000 cannabis producers, along with its inability to rein in black market operators, has been an unmitigated disaster for the country's top legal cultivators. Despite billions of dollars being spent on state-of-the-art cultivation facilities, brick-and-mortar retail outlets, and virtual storefronts, Canada's largest cannabis companies have been losing money at an alarming rate due to a vast oversupply of product in the country. In turn, profit margins have cratered across the industry, spurring some notable cannabis companies like Aurora Cannabis (NASDAQ: ACB), SNDL, and Tilray Brands to diversify into non-cannabis businesses like alcohol and vegetables in an effort to become cash-flow-positive.
Here's why cannabis stocks such as Aurora Cannabis and Canopy Growth remain high-risk bets for TSX investors. The post Are Cannabis Stocks a Good Buy in April 2023? appeared first on The Motley Fool Canada.
Marijuana stocks have performed poorly over the last two years. Cannabis analytics firm BDSA estimates that global cannabis sales will reach $57 billion by 2026, a 13% annual growth forecast from $30 billion in 2021, with bulk of this growth expected to be driven by the Canadian and American markets. Investment opportunities seem lucrative, and investors with a higher risk appetite might stand to profit handsomely in the long run in this volatile industry.
Canadian marijuana company Aurora Cannabis (NASDAQ: ACB) is having another bad day. The pot seller's shares were down by a noteworthy 4.34% on moderate volume as of 2:05 p.m. ET on Monday. Since the start of the year, Aurora's stock has now shed 27.5% of its value, and the share price has fallen well below the Nasdaq's $1 bid requirement, triggering a noncompliance notice from the exchange last month.
Key Takeaways; Cannabis Sector Aurora announced the repurchase of convertible senior notes worth approximately $47 million, saving the company $2.6 million in annualized interest payments. Jushi Holdings reported preliminary Q4 and record full year 2022 financial results. Curaleaf announced $20 million acquisition in Key Takeaways; Psychedelic Sector Awakn’s proprietary treatment protocol for alcohol use disorder […] The post Weekly Roundup on the Cannabis Sector & Psychedelic Sector appeared fi
Aurora Cannabis Inc. ("Aurora" or the "Company") (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, today announced that it has repurchased an aggregate of approximately $46.6 million (US$34.3 million) principal amount of its convertible senior notes ("Notes") at a total cost, including accrued interest, of $45.6 million (US$33.6 million) in cash, saving $2.6 million in annualized interest payments. Following completion of this repurchase, Aurora will have approximatel
Restructuring and changes in strategy are moves that businesses often deploy when they're facing challenges and headwinds. While Aurora Cannabis (NASDAQ: ACB) has been slashing costs and changing its operations in recent years, the company isn't out of the woods by any stretch. Among the biggest moves that Aurora has made in recent years has been to shift its business more toward medical marijuana.
Aurora Cannabis (NASDAQ: ACB) is one of the few Canadian cannabis retailers that is still seeing revenue growth, despite price compression and illegal sales negatively impacting the industry. The company is still losing money, but it appears to be edging its way toward profitability. Aurora's path to success includes branching out to international markets while focusing more on medical marijuana sales at home.
Aurora Cannabis Inc. ("Aurora" or the "Company") (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, today announced receipt of a notification letter (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") dated March 24, 2023, advising that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1) as the bid price of the Company's listed securities had closed at less than US$1.00 per share over the last 30 consecutive business days (the "Min